Table 1.
RNA sequencing and microarray analyses of differentially expressed circRNAs in breast cancer.
| Samples | Detection method | Differentially expressed circRNAs | References |
|---|---|---|---|
| 4 pairs of TNBC and adjacent noncancerous tissues | RNA sequencing | 47 were up-regulated and 307 were down-regulated (FC≥2, P< 0.05) | (32) |
| 3 pairs of breast cancer and corresponding adjacent non-cancerous tissues | RNA sequencing | 85 were upregulated and 67 were downregulated.(FDR ≤ 0.001, FC≥2) | (51) |
| 8 patients’ specimens (TNBC, N = 4; luminal A, N = 4) and 3 normal mammary gland tissues (NMGT) | RNA sequencing | 140 upregulated and 95 downregulated circRNA were identified, including 215 and 73 circRNAs for the TNBC and LA subtypes, respectively (FC>1.5, P<0.05) | (52) |
| 4 TNBC and 3 NMGT | RNA sequencing | 122 upregulated and 93 downregulated circRNA were identified (FC>1.5, P<0.05) | (52) |
| 4 LA and 3 NMGT | RNA sequencing | 55 upregulated and 18 downregulated circRNA were identified (FC>1.5, P<0.05) | (52) |
| 3 pairs of breast cancer tissues with or without metastasis | RNA sequencing | A total of 51 circRNAs were differentially expressed (FC>1.5, P< 0.05) | (53) |
| 4 pairs of TNBC tissues and adjacent non-cancerous tissues | RNA sequencing | 47 were upregulated, whereas 307 were downregulated (FC>2.0, P< 0.05) | (54) |
| 4 pairs of breast cancer lesions and matched adjacent normal-appearing tissues | microarray | 715 circRNAs were upregulated and 440 circRNAs were downregulated (FC≥2, P<0.05) | (55) |
| 3 pairs of TNBC tissues and matched normal mammalian tissues | microarray | 173 circRNAs were up-regulated, and 77 circRNAs were down-regulated (FC≥1.5, P<0.05, FDR< 0.05) | (56) |
| 4 pairs of breast cancer tissues and adjacent noncancerous tissues | microarray | A total of 2,587 circRNAs with 1.5 fold of upregulation or downregulation (FC>1.5, P<0.05) | (57) |
| 4 pairs of breast cancer tissues and adjacent normal tissues | microarray | 15 circRNAs upregulated and 16 circRNAs downregulated (FC>4.0, P<0.05) | (58) |
| 5 pairs of breast tumor tissues and matched non-tumor tissues | microarray | A total of 716 circRNAs that were differently expressed (FC>1.5, P<0.05) | (59) |
| 3 pairs of breast cancer tissues and their adjacent non-tumor tissues | microarray | 1953 circRNAs were upregulated and 1700 circRNAs were downregulated (FC>2.0 and P< 0.05) | (60) |
| 3 pairs of TNBC and adjacent normal tissues | RNA sequencing | 1307 circRNAs were up-regulated and 3726 circRNAs were down-regulated (FC≥2, P< 0.05) | (61) |
| 5 pairs of breast cancer tissues and corresponding nontumorous tissues | RNA sequencing | 30 were up-regulated and 19 were down-regulated (FC>2, P< 0.001) | (62) |
| 2 pairs of BCLM tissues and primary tumor tissues | microarray | 559 were upregulated and 661 were downregulated (FC>2, P< 0.05) | (63) |
| 6 pairs of breast cancer/adjacent tissues | microarray | 2,375 were upregulated, whereas 1,995 were downregulated (FC>2.0 or <0.5, P<0 .05) | (64) |
| 3 pairs of breast cancer tissues and paired noncancerous tissues | microarray | 292 were upregulated and 228 were downregulated (FC≥2, P< 0.05) | (65) |
BC, breast cancer; LA, luminal A; TNBC, triple-negative breast cancer; NMGT, normal mammary gland tissues; BCLM, breast cancer liver metastases; FC, fold change; FDR, false discovery rate.